Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > July 28, 2025
Daily News
July 28, 2025
- Japan Hypertension Society to Release Revised Treatment Guidelines in August
July 28, 2025
- Two Oral Drugs Found to Exceed ADI for Red No. 3, MHLW Reports
July 28, 2025
- Takeda Alumni Link with Osaka Biz Lobby to Support Drug Discovery
July 28, 2025
- PMDA Launches Advisory Program for Academia, Startups Developing New Modalities
July 28, 2025
- AstraZeneca, Koriyama City Team Up to Drive NCD Prevention and Early Detection
July 28, 2025
- Fuji Pharma Kicks Off Japan PIII for Alyssa in Endometriosis
July 28, 2025
- Flatiron Triples UK, Germany, Japan Oncology RWD Network in One Year
July 28, 2025
- Pharmaceutical Policy at a Crossroad amid Political Upheaval in Japan
July 28, 2025
- Beyond the Bench: Why Biopharma Needs Strategic Thinkers
July 28, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…